Abstracts

2019


2018


- Richardson H, Knight B, Chen G, Luo S, Massey T, Goss PE, Lazarus P. Association between the UGT2B17 gene deletion, exemestane metabolites and vasomotor QOL in


2017


• Rodriguez-Romo LN, Meyer R, Pater JL, Sussman J, Zhang S, Hongbo L, Winter JN,


- Wells C, Siu LL, Shapiro JD, Tu D, Jonker DJ, Karapetis CS, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ. Age as a predictive and prognostic factor for targeted

- Davis ID, Stockler MR, Martin AJ, Hague W, Coskinas X, Yip S, Tu E, Lawrence NJ,


study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226).
EORTC-NCI-AACR Symposium 2016.


deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304). J Clin Oncol 33[suppl; abstr TPS5077].


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Group (AGITG)—Final overall and subgroup results. J Clin Oncol 33[ suppl; abstr 4003].

Pennimment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.


Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). Blood (ASH Annual Meeting Abstracts) 126[23]. 2015.


2014

• Kangarloo SB, Ng ESM, Bramwell VHC, Pritchard KI, Shepherd LE, Tu D, Magliocco


• Sternberg CN, Skoneczna IA, Kerst JM, Fossa SD, Albers P, Agerbaek M, Dumez H, De Santis M, Theodore C, Leahy MG, Chester JD, Verbaeys A, Caty A, Daugaard G,


2013

- Goodwin PJ, Parulekar W, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


2012


- Chapman J-AW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE,


• Leighl NB, Tsao MS, Ho C, Shepherd FA, Murray N, Goffin J, Nicholas G, Seymour L, Goss GD, Bradbury P. NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC. EORTC-NCI-AACR Symposium [abstr 607], 2012.

• Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


2011


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Cuffe S, Graziano S, Bourrejdem A, Pignon J-P, Ezzalfan M, Seymour L, Strevel E,
Burkes R, Capelletti M, Janne PA, Tsao MN, Shepherd FA. A pooled exploratory analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[6 suppl 2, abstr O42.01], S462, 2011.


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

hour infusion. EORTC-NCI-AACR Symposium [abstr 512], 2010.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2009


- Bradbury PA, Twumasi-Ankrah P, Ding K, Shepherd FA, Goss G, Leighl NB, Laurie S, Seymour L. Known Brain Metastases: A valid exclusion criterion in non-small cell lung cancer (NSCLC) clinical trials? An audit of the eligibility criteria in NSCLC trials, and an evaluation of treatment delivery, toxicity and survival experienced by patients with brain


- Craddock KJ, Buys TPH, Zhu CQ, Strumphi D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


Jonker DJ, Karapetis C, Harbison C, O’Callaghan CJ, Tu D, Simes RJ, Xu L, Moore MJ,


- Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: Is this a...
patient-centered or tumor-centered endpoint? J Clin Oncol 27[15s], 2009.


- Palmer M, Broxtermann J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


114[22, abstr 2631], 2009.


2008.


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


Part I], 399s, 2008.


2007


• Ding K. Determining the cutoff points for a predictive continuous biomarker with time to


• Lee CW, Pater J, Martin J, MacRae R, Laurie SA, Ung Y, Willman C, Soroka D, Shepherd FA. A survey of Canadian practice in management of malignant pleural


• Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J,

- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.

2006

2006.


gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU before and after CI 5-FU and radiotherapy: Interim toxicity results from Intergroup trial CALGB 80101. ASCO Gastrointestinal Cancers Symposium [Abstr 61], 2006.


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


2005


• Au H, Goldstein D, Ding K, Parulekar W, Gallinger S, Moore M. Does epidermal growth factor receptor inhibitor skin toxicity affect QOL? Results from a NCIC Clinical Trials Group. Quality of Life Research 14[9], 2135, 2005.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


• Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.


2004


Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. N9741: Oxaliplatin (Oxal) + CPT-11 or 5-fluorouracil (5FU)/leucovorin (LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study.

Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


2003

- Brundage M, Bezjak A, Tu D, Palmer M, Dixon P, Pater J. How should palliation be measured - Illustrative examples from the NCIC CTG palliative thoracic radiation trial.
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


Ernst S, Tannock I, Venner P, Winquist E, Reyno L, Walker H, Ding K, Elliott C,


• Wolf J, Hamilton M, Eisenhauer E, Calvert A, Grimshaw R, Murtomaki E, Rusk J, Ptaszynski M, Onetto N. Pharmacokinetics of NX211 (liposomal lurtotecan) using a limited sampling model in a phase II trial of patients with ovarian cancer.
2001

- Connors J, Klimo P, Adams G, Burns B, Cooper I, Meyer R, O'Reilly S, Pater J, Quirt I,


2000


**1999**


• Chouinard E, Goel R, Hirte H, Stewart D, Hurak S, Waterfield B, Matthews S, Elias I,


Eisenhauer E, MacNeil M. Is there a role of high dose chemotherapy in the standard management of common solid tumors? International Congress on Anti-Cancer
Treatment, 1998.


Dancey J, Zee B, Osoba D, Whitehead M, Palmer M, Shepherd F, Pater J. Gender specific differences on baseline quality of life assessments in lung cancer patients: results from four NCIC Clinical Trials Group studies. Lung Cancer 18 (suppl 1), 203,
1997.


- Swenerton K, for the European-Canadian Ovarian Cancer Intergroup (EORTC, NCI-C,


1996


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


1995


- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


- Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQC30 based on reliability testing in large samples of patients with cancer. Quality of Life

1994


1993


Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy. Eur.J.Can. 29A(Suppl.6), S208, 1993.

- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.

1992


• Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


• Vandenberg T, Pritchard KI, Eisenhauer E, Trudeau M, Norris B, Lopez P, Verma S,


1991

- Palmer M, Koski B, Goodlow J, Zee B. So clean it squeaks -- comparison of data collected by two independent groups on the same trial. Controlled Clin.Trials 12(5), 693,


1990


Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1987


O'Dwyer P, Eisenhauer E, Hoth D. Deoxycoformycin in lymphoid malignancies, an overview. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1986.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984


1983


1981
